CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Name: CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Published: 2026
License: Public Domain

National Cancer Institute (NCI) · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

acute lymphoblastic leukemia, b-all, cd-22 expressing tumor, cd-19 expressing tumor, adoptive immunotherapy, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Related documents